The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure

The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure

Abstract Background CKD is common in heart failure (HF) and associated with morbidity and mortality, yet life-prolonging medications such as renin-angiotensin-aldosterone inhibitors (RAASi) are underused due to risk of hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is a potassium-binding medica...

Full description

Bibliographic Details
Main Authors: Daniel Murphy, Irina Chis Ster, Juan-Carlos Kaski, Lisa Anderson, Debasish Banerjee
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Nephrology
Subjects:
Chronic kidney disease
Heart failure
RAAS
Potassium binder
Randomised
Online Access:https://doi.org/10.1186/s12882-021-02439-2

Internet

https://doi.org/10.1186/s12882-021-02439-2

Similar Items